Information Session: Developing a Consensus-Based Assessment Framework for Genetic and Genomic Biomarkers in Cancer Care

Date and time (free online event):     
May 13, 2025, at 1:00 p.m. ET (Industry representatives)
May 15, 2025, at 12:00 p.m. ET (Patient community)
May 29, 2025, at 1:00 p.m. ET (Clinicians and clinical societies)

Within the rapidly emerging field of precision medicine, more complex, expensive, and promising genetic and genomic tests are being developed to identify biomarkers that can help inform cancer treatment and care. Health decision-makers across jurisdictions in Canada make decisions about implementing tests for various biomarkers that may inform cancer prevention, diagnosis, treatment, and prognosis; however, current approaches to evaluation and decision-making are variable and inconsistent, which has been observed to introduce inequities in the availability of and access to biomarker testing and precision medicine technologies.  

Canada’s Drug Agency has brought together a time-limited advisory panel tasked with developing a consensus-based assessment framework to support standardized, efficient, and transparent assessment of genetic and genomic biomarkers in cancer care in Canada.  

Join us for an informational webinar to learn more about the project’s approach and progress to date. The webinar will include details on how you can offer your contributions during the feedback period, which will open in June 2025.  

Three distinct sessions will be offered for different audiences. Please register for the session that best suits your role.  

1. Industry representatives: Tuesday, May 13, 2025, 1:00 p.m. to 2:00 p.m. ET
    Register now
2. Patient community: Thursday, May 15, 2025, 12:00 p.m. to 1:00 p.m. ET
    Register now
3. Clinicians and clinical societies: Thursday, May 29, 2025, 1:00 p.m. to 2:00 p.m. ET
    Register now 

Recordings will be made available after each webinar.